Silexion Therapeutics Corp

Silexion Therapeutics Corp is a clinical-stage biotechnology company focused on oncology, specifically developing proprietary therapies for cancers driven by Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations. The company's technology silences oncogenes using chemically modified small interfering RNA (siRNA) constructs that prompt cancer cells to degrade messenger RNA. Its lead product candidate, SIL204, is a second-generation siRNA designed to halt the production of mutated KRAS proteins. SIL204 is administered both intratumorally and systemically via subcutaneous injection in combination with standard chemotherapy to treat patients with locally advanced pancreatic cancer.

The company operates primarily through its subsidiary, Silexion Therapeutics Ltd., in Israel, with operations and corporate entities connected to the Cayman Islands. Its principal executive offices and headquarters are located in Ramat-Gan, Israel. Silexion Therapeutics Corp does not generate commercial product sales and relies on third-party organizations to conduct preclinical and clinical trials and provide manufacturing capabilities.

Summary of the business section of Silexion Therapeutics's latest annual report, written by StockData.

“As of the date of this Annual Report, we have thirteen full-time and one part-time employees. All of our employees are based in Israel. None of our employees is represented by labor unions or covered by collectiv”